Cardiol Therapeutics (CRDL) Amortizatization of Intangibles (2020 - 2024)
Cardiol Therapeutics' (CRDL) quarterly Amortizatization of Intangibles came in at $123252.7 in Q3 2024, up 682.69% YoY from $15747.3 in Q4 2023, and up 698.52% on a QoQ basis from $15435.1 in Q2 2024.
Cardiol Therapeutics (CRDL) Amortizatization of Intangibles (2020 - 2024) Analysis & Trends
Cardiol Therapeutics (CRDL) has 5 years of Amortizatization of Intangibles data on file, last reported at $123252.7 in Q3 2024.
- Quarterly Amortizatization of Intangibles rose 682.69% year-over-year to $123252.7 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $170101.9 (up 168.87% YoY) and the FY2021 annual result came in at $67382.5, up 6.9% from the prior year.
- Amortizatization of Intangibles improved to $123252.7 in Q3 2024, from $15435.1 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $123252.7 in Q3 2024 to a low of $15435.1 in Q2 2024.
- A 5-year average of $23886.5 and a median of $16375.8 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles retreated 6.31% — and 2024, when it surged 682.69%.
- Tracing CRDL's Amortizatization of Intangibles over 5 years: stood at $16193.3 in 2020, then advanced by 3.43% to $16748.1 in 2021, then slipped by 3.35% to $16186.8 in 2022, then slipped by 2.71% to $15747.3 in 2023, then surged by 682.69% to $123252.7 in 2024.
- The last three Amortizatization of Intangibles figures came in at $123252.7 (Q3 2024), $15435.1 (Q2 2024), and $15666.8 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Cardiol Therapeutics | 213.21 Mn | 194.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 123,252.67 |
| Sep 30, 2024 | 123,252.67 |
| Jun 30, 2024 | 15,435.11 |
| Jun 30, 2024 | 15,435.11 |
| Mar 31, 2024 | 15,666.75 |
| Mar 31, 2024 | 15,666.75 |
| Sep 30, 2023 | 15,747.34 |
| Sep 30, 2023 | 15,747.34 |
| Jun 30, 2023 | 15,716.14 |
| Jun 30, 2023 | 15,716.14 |
| Mar 31, 2023 | 15,615.73 |
| Mar 31, 2023 | 15,615.73 |
| Sep 30, 2022 | 16,186.78 |
| Sep 30, 2022 | 16,186.78 |
| Jun 30, 2022 | 16,558.22 |
| Jun 30, 2022 | 16,558.22 |
| Mar 31, 2022 | 16,666.62 |
| Mar 31, 2022 | 16,666.62 |
| Dec 31, 2021 | 16,748.12 |
| Dec 31, 2021 | 16,748.12 |